EGFR and lung adenocarcinoma: Although the identification of EGFR mutations and the advancement of EGFR tyrosine kinase inhibitors (EGFR-TKIs) have enhanced patient outcomes, the emergence of drug resistance impedes the effectiveness and long-term success of such treatments, presenting a significant challenge in the management of lung adenocarcinoma (Du et al., 2021; Hrustanovic et al., 2013).